AZD 7624

Drug Profile

AZD 7624

Alternative Names: AZD-7624

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 30 Sep 2016 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in United Kingdom (Inhalation) because of unfavourable safety and efficacy results (AstraZeneca pipeline, November 2016; AstraZeneca quarterly report, November 2016)
  • 30 Sep 2016 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Netherlands, Argentina, Chile, Peru, South Africa, USA (Inhalation) because of unfavourable safety and efficacy results (AstraZeneca pipeline, November 2016; AstraZeneca quarterly report, November 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (Inhalation, Aerosol)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top